Published in Cancer Epidemiol Biomarkers Prev on December 01, 2007
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer (2008) 1.82
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer (2009) 1.54
Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Res (2010) 1.51
Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol (2009) 1.33
Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS One (2010) 1.28
11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat (2012) 1.26
Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Br J Cancer (2009) 1.19
Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. J Natl Cancer Inst (2010) 1.17
Genetic variants in XRCC2: new insights into colorectal cancer tumorigenesis. Cancer Epidemiol Biomarkers Prev (2009) 1.10
Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study. BMC Cancer (2009) 1.05
Progesterone receptor gene variants and risk of endometrial cancer. Carcinogenesis (2010) 0.98
Association of BRCA2 N372H polymorphism with cancer susceptibility: a comprehensive review and meta-analysis. Sci Rep (2014) 0.89
Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Hum Mol Genet (2011) 0.85
Analyzing association of the XRCC3 gene polymorphism with ovarian cancer risk. Biomed Res Int (2014) 0.84
Impact of XRCC2 Arg188His polymorphism on cancer susceptibility: a meta-analysis. PLoS One (2014) 0.81
DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population. J Hematol Oncol (2013) 0.81
XRCC3 Thr241Met polymorphism and ovarian cancer risk: a meta-analysis. Tumour Biol (2013) 0.80
Polymorphisms in genes hydroxysteroid-dehydrogenase-17b type 2 and type 4 and endometrial cancer risk. Gynecol Oncol (2010) 0.80
Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study. Carcinogenesis (2011) 0.79
Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium. PLoS One (2011) 0.78
RAD52 variants predict platinum resistance and prognosis of cervical cancer. PLoS One (2012) 0.78
BRCA2 N372H Polymorphism and Risk of Epithelial Ovarian Cancer: An Updated Meta-Analysis With 2344 Cases and 9672 Controls. Medicine (Baltimore) (2015) 0.75
Associations between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and ovarian cancer. Oncotarget (2016) 0.75
Microarray expression profiling of long non-coding RNAs in epithelial ovarian cancer. Oncol Lett (2017) 0.75
Haplotype analysis of XRCC2 gene polymorphisms and association with increased risk of head and neck cancer. Sci Rep (2017) 0.75
A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res (1988) 77.80
Genetic and environmental contributions to alcohol dependence risk in a national twin sample: consistency of findings in women and men. Psychol Med (1997) 5.69
Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst (1998) 4.05
Incessant ovulation--a factor in ovarian neoplasia? Lancet (1971) 3.95
Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst (2004) 3.53
Breast cancer in Australian women under the age of 40. Cancer Causes Control (1998) 2.08
A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet (2000) 1.80
Risk prediction models for familial breast cancer. Future Oncol (2006) 1.68
Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol (1996) 1.62
Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab (2006) 1.56
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology (2001) 1.54
Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res (2001) 1.51
Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer (2005) 1.44
Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene (2000) 1.38
Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis (2006) 1.35
Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst (2006) 1.35
A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res (1997) 1.27
Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst (2002) 1.26
Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol (Oxf) (1998) 1.26
Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr Rev (1998) 1.22
Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group. Int J Cancer (1995) 1.18
Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Res (1988) 1.18
Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.14
Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics (2000) 1.11
Estrogen replacement therapy and ovarian cancer. Epidemiology (2004) 1.09
BRCA2 Arg372Hispolymorphism and epithelial ovarian cancer risk. Int J Cancer (2003) 1.05
Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol (1997) 1.05
Site-directed mutagenesis of the putative active site of human 17 beta-hydroxysteroid dehydrogenase type 1. Biochem J (1994) 1.04
Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis (1999) 1.03
Common variants in RB1 gene and risk of invasive ovarian cancer. Cancer Res (2006) 1.01
Human familial and sporadic breast cancer: analysis of the coding regions of the 17 beta-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay. Hum Genet (1994) 1.01
The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev (2001) 0.92
Structural basis of the multispecificity demonstrated by 17beta-hydroxysteroid dehydrogenase types 1 and 5. Mol Cell Endocrinol (2006) 0.92
SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2003) 0.90
Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2001) 0.90
The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer. Cancer Res (1999) 0.89
Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer (2001) 0.88
5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics (2002) 0.87
CYP17 promotor polymorphism and ovarian cancer risk. Int J Cancer (2000) 0.85
Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients. Dis Markers (2000) 0.84
Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer. Int J Cancer (2000) 0.83
Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data. Gynecol Endocrinol (2004) 0.81
Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. Cancer Epidemiol Biomarkers Prev (2002) 0.81
RAD52 Y415X truncation polymorphism and epithelial ovarian cancer risk in Australian women. Cancer Lett (2005) 0.81
Finding the missing heritability of complex diseases. Nature (2009) 67.95
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37
Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A (2006) 10.32
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature (2009) 8.12
Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet (2010) 7.62
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet (2008) 6.97
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03
Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst (2008) 5.82
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat (2008) 5.52
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med (2015) 4.77
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res (2004) 4.54
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA (2007) 4.33
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol (2012) 3.86
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81